. "Ovlivn\u011Bn\u00ED sign\u00E1ln\u00EDch drah mTOR a MAPK inhibic\u00ED kin\u00E1zov\u00E9 aktivity Src - v\u00FDznam pro individualizovanou protin\u00E1dorovou terapii"@cs . . . . "Aktivita proteinu Src je zv\u00FD\u0161en\u00E1 v mnoha typech lidsk\u00FDch n\u00E1dor\u016F. Na\u0161e p\u0159edchoz\u00ED v\u00FDsledky uk\u00E1zaly, \u017Ee potla\u010Den\u00EDm tyrosinkin\u00E1zov\u00E9 aktivity Src doch\u00E1z\u00ED k inhibici aktivity a serin/treonin-specifick\u00E9 fosforylace efektorov\u00FDch protein\u016F v sign\u00E1ln\u00ED dr\u00E1ze \u0159\u00EDzen\u00E9 mTORem. Krom\u011B rapamycinu a jeho analog\u016F, inhibitor\u016F mTORu vyu\u017E\u00EDvan\u00FDch v protin\u00E1dorov\u00E9 l\u00E9\u010Db\u011B, tak\u00E9 inhibitory proteinu Src mohou p\u0159edstavovat v\u00FDznamn\u00FD terapeutick\u00FD prost\u0159edek pro l\u00E9\u010Dbu n\u00E1dor\u016F, zejm\u00E9na t\u011Bch, v kter\u00FDch je mTOR dr\u00E1ha reaktivov\u00E1na. Z\u00E1m\u011Brem navrhovan\u00E9ho projektu je zjistit \u00FA\u010Dinnost potla\u010Den\u00ED aberantn\u011B zv\u00FD\u0161en\u00E9 aktivity sign\u00E1ln\u00EDch drah mTORu a MAPKin\u00E1z v n\u00E1dorov\u00FDch bu\u0148k\u00E1ch pomoc\u00ED inhibice aktivity Src, tedy ur\u010Dit, jak\u00FDm zp\u016Fsobem je tyrosinkin\u00E1zov\u00E1 aktivita Src zapojena do deregulace p\u0159enosu sign\u00E1l\u016F kask\u00E1dami serin/treonin-specifick\u00FDch kin\u00E1z. Budou studov\u00E1ny vybran\u00E9 typy n\u00E1dorov\u00FDch bun\u011Bk se zv\u00FD\u0161enou aktivitou Src, zejm\u00E9na bu\u0148ky karcinomu plic a melanomu. V\u00FDsledky p\u0159isp\u011Bj\u00ED k racion\u00E1ln\u00ED protin\u00E1dorov\u00E9 l\u00E9\u010Db\u011B proteinkin\u00E1zov\u00FDmi inhibitory."@cs . "Control of mTOR and MAPK pathways by Src tyrosine kinase activity - implication for cancer therapy by protein kinase inhibitors"@en . . . "3888"^^ . "2010-09-01+01:00"^^ . "3888"^^ . . "2013-06-30+01:00"^^ . "0"^^ . . . "1"^^ . "0"^^ . "Tyrosine kinase activity of Src is up-regulated in numerous types of human cancer and Src inhibitors are used as efficient anticancer drugs. Pre-clinical data and clinical trials showed strong effect of tyrosine kinase inhibitors in cancer therapy. Our previous findings has shown that the suppression of Src kinase activity results in the inhibition of the serine/threonine-specific phosphorylation of effector proteins in the mTOR signalling pathway. It indicates that, besides rapamycin and its analogues which are tested in clinical trials, Src inhibitors are important therapeutic agents against tumors with different deregulated signal transduction pathways.The aim of the project is to elucidate how Src tyrosine kinase activity is involved in the deregulated signalling of two important pathways, the mTOR pathway and the MAPK cascade, in cancer cells."@en . . "0"^^ . "mTOR; Src; Akt; MAPK; signalling pathways; lung carcinoma; melanoma; tyrosine kinase inhibitors; anticancer therapy"@en . . "0"^^ .